MacFarland RT - Search Results

1

Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers.

Nyunt MM, Becker S, MacFarland RT, Chee P, Scarborough R, Everts S, Calandra GB, Hendrix CW. Nyunt MM, et al. Among authors: macfarland rt. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65. doi: 10.1097/QAI.0b013e3181627566. J Acquir Immune Defic Syndr. 2008. PMID: 18362694

2

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.

Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao YJ, Wiggins IP, Conley J, MacFarland RT, Park JG, Lalama C, Snyder S, Kallungal B, Klingman KL, Hendrix CW. Stone ND, et al. Among authors: macfarland rt. Antimicrob Agents Chemother. 2007 Jul;51(7):2351-8. doi: 10.1128/AAC.00013-07. Epub 2007 Apr 23. Antimicrob Agents Chemother. 2007. PMID: 17452489 Free PMC article. Clinical Trial.

3

Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers.

Cao YJ, Flexner CW, Dunaway S, Park JG, Klingman K, Wiggins I, Conley J, Radebaugh C, Kashuba AD, MacFarland R, Becker S, Hendrix CW. Cao YJ, et al. Antimicrob Agents Chemother. 2008 May;52(5):1630-4. doi: 10.1128/AAC.01460-07. Epub 2008 Feb 19. Antimicrob Agents Chemother. 2008. PMID: 18285477 Free PMC article. Clinical Trial.

4

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, Bridger GJ, Badel K, MacFarland RT, Henson GW, Calandra G; AMD3100 HIV Study Group. Hendrix CW, et al. Among authors: macfarland rt. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1253-62. doi: 10.1097/01.qai.0000137371.80695.ef. J Acquir Immune Defic Syndr. 2004. PMID: 15385732 Clinical Trial.

5

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.

Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. Hendrix CW, et al. Among authors: macfarland rt. Antimicrob Agents Chemother. 2000 Jun;44(6):1667-73. doi: 10.1128/AAC.44.6.1667-1673.2000. Antimicrob Agents Chemother. 2000. PMID: 10817726 Free PMC article. Clinical Trial.

6

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.

MacFarland R, Hard ML, Scarborough R, Badel K, Calandra G. MacFarland R, et al. Biol Blood Marrow Transplant. 2010 Jan;16(1):95-101. doi: 10.1016/j.bbmt.2009.09.003. Epub 2009 Sep 10. Biol Blood Marrow Transplant. 2010. PMID: 19748593 Free article. Clinical Trial.

7

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Stewart DA, Smith C, MacFarland R, Calandra G. Stewart DA, et al. Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018. Biol Blood Marrow Transplant. 2009. PMID: 19135941 Free article. Clinical Trial.

8

Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.

Moyle G, DeJesus E, Boffito M, Wong RS, Gibney C, Badel K, MacFarland R, Calandra G, Bridger G, Becker S; X4 Antagonist Concept Trial Study Team. Moyle G, et al. Clin Infect Dis. 2009 Mar 15;48(6):798-805. doi: 10.1086/597097. Clin Infect Dis. 2009. PMID: 19193109 Clinical Trial.

9

Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.

Bodart V, Anastassov V, Darkes MC, Idzan SR, Labrecque J, Lau G, Mosi RM, Neff KS, Nelson KL, Ruzek MC, Patel K, Santucci Z, Scarborough R, Wong RS, Bridger GJ, Macfarland RT, Fricker SP. Bodart V, et al. Among authors: macfarland rt. Biochem Pharmacol. 2009 Oct 15;78(8):993-1000. doi: 10.1016/j.bcp.2009.06.010. Epub 2009 Jun 18. Biochem Pharmacol. 2009. PMID: 19540208

10

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

Lack NA, Green B, Dale DC, Calandra GB, Lee H, MacFarland RT, Badel K, Liles WC, Bridger G. Lack NA, et al. Among authors: macfarland rt. Clin Pharmacol Ther. 2005 May;77(5):427-36. doi: 10.1016/j.clpt.2004.12.268. Clin Pharmacol Ther. 2005. PMID: 15900288 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page